Johnson & Johnson (JNJ) : Factory Mutual Insurance Co reduced its stake in Johnson & Johnson by 10.68% during the most recent quarter end. The investment management company now holds a total of 920,300 shares of Johnson & Johnson which is valued at $113,196,900 after selling 110,000 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Jul 12, 2016.Johnson & Johnson makes up approximately 1.45% of Factory Mutual Insurance Co’s portfolio.
Other Hedge Funds, Including , Svenska Handelsbanken Ab (publ) reduced its stake in JNJ by selling 34,399 shares or 78.54% in the most recent quarter. The Hedge Fund company now holds 9,401 shares of JNJ which is valued at $1,156,323. Johnson & Johnson makes up approx 0.07% of Svenska Handelsbanken Ab (publ)’s portfolio.Beacon Capital Management reduced its stake in JNJ by selling 544 shares or 19.82% in the most recent quarter. The Hedge Fund company now holds 2,201 shares of JNJ which is valued at $270,393. Johnson & Johnson makes up approx 0.02% of Beacon Capital Management’s portfolio.Cohen Lawrence B boosted its stake in JNJ in the latest quarter, The investment management firm added 1,320 additional shares and now holds a total of 36,390 shares of Johnson & Johnson which is valued at $4,470,512. Johnson & Johnson makes up approx 2.63% of Cohen Lawrence B’s portfolio.Spirit Of America Management Corpny reduced its stake in JNJ by selling 3,200 shares or 26.64% in the most recent quarter. The Hedge Fund company now holds 8,810 shares of JNJ which is valued at $1,082,309. Johnson & Johnson makes up approx 0.16% of Spirit Of America Management Corpny’s portfolio.Private Asset Management Inc reduced its stake in JNJ by selling 1,247 shares or 0.83% in the most recent quarter. The Hedge Fund company now holds 148,730 shares of JNJ which is valued at $18,271,481. Johnson & Johnson makes up approx 3.19% of Private Asset Management Inc’s portfolio.
Johnson & Johnson closed down -0.18 points or -0.15% at $123 with 71,92,765 shares getting traded on Friday. Post opening the session at $123.77, the shares hit an intraday low of $122.71 and an intraday high of $124.3 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.